Savara Inc.
SVRA
$0.09
Change (1 day)
$5.70
Year High
$2.82
Year Low
Categories
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
P/B ratio for Savara Inc. (SVRA)
P/B ratio as of 2023: 5.53
According to Savara Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5.53. At the end of 2022 the company had a P/B ratio of 2.20.
P/B ratio history for Savara Inc. from 2000 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 5.53 |
| 2022 | 2.20 |
| 2021 | 1.15 |
| 2020 | 1.06 |
| 2019 | 1.76 |
| 2018 | 2.33 |
| 2017 | 2.18 |
| 2016 | -0.57 |
| 2015 | 2.85 |
| 2014 | 1.17 |
| 2013 | 0.74 |
| 2012 | 0.65 |
| 2011 | 0.29 |
| 2010 | 1.29 |
| 2009 | 6.12 |
| 2008 | 1.13 |
| 2007 | 1.30 |
| 2006 | 10.94 |
| 2005 | -25.07 |
| 2004 | 4.58 |
| 2003 | 16.60 |
| 2002 | -37.08 |
| 2001 | -46.15 |
| 2000 | 1.16 |